{"name": "Nabriva Therapeutics",
 "permalink": "nabriva-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/nabriva-therapeutics",
 "homepage_url": "http://www.nabriva.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2001,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "office@nabriva.com",
 "phone_number": "+43 (0)1 740 93-0",
 "description": "",
 "created_at": "Thu Oct 29 02:21:08 UTC 2009",
 "updated_at": "Sat Apr 28 01:17:12 UTC 2012",
 "overview": "\u003Cp\u003ENabriva Therapeutics AG operates as a biopharmaceutical company that engages in the discovery and development of antibiotics for use in community and hospital infections. The company focuses on antibiotic classes, such as pleuromutilins designed for oral and topical application; and injectable broad-spectrum anti-MRSA cephalosporins. Its products include Oral Pleuromutilins BC-3205 and BC-3781 for multi-drug resistant (MDR) pathogens, including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia, and vancomycin resistant Enterococcus faecium; Topical Pleuromutilin BC-7013 for the treatment of various bacterial associated, or derived dermatological diseases; and Cephalosporins for the treatment of hospital infections. The company was formerly known as Antibiotic Research Institute and changed its name to Nabriva Therapeutics AG in February, 2006. Nabriva Therapeutics AG was founded in 2001 is based in Vienna, Austria.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       92],
      "assets/images/resized/0006/4061/64061v1-max-150x150.jpg"],
     [[166,
       102],
      "assets/images/resized/0006/4061/64061v1-max-250x250.jpg"],
     [[166,
       102],
      "assets/images/resized/0006/4061/64061v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Co-Founder",
    "person":
     {"first_name": "Rodger",
      "last_name": "Novak",
      "permalink": "rodger-novak",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$22M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://onbiovc.com/nabriva-therapeutics-ag-series-b-22m/",
    "source_description": "Nabriva Therapeutics, AG: Series B $22M",
    "raised_amount": 22000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 1,
    "funded_day": 17,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "HBM BioVentures",
         "permalink": "hbm-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0482/50482v1-max-150x150.png"],
             [[156,
               27],
              "assets/images/resized/0005/0482/50482v1-max-250x250.png"],
             [[156,
               27],
              "assets/images/resized/0005/0482/50482v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Wellcome Trust",
         "permalink": "wellcome-trust",
         "image":
          {"available_sizes":
            [[[150,
               12],
              "assets/images/resized/0002/9701/29701v2-max-150x150.jpg"],
             [[250,
               20],
              "assets/images/resized/0002/9701/29701v2-max-250x250.jpg"],
             [[450,
               37],
              "assets/images/resized/0002/9701/29701v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GLS Ventures",
         "permalink": "gls-ventures",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Venture Fund",
         "permalink": "novartis-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0005/9083/59083v2-max-150x150.png"],
             [[250,
               117],
              "assets/images/resized/0005/9083/59083v2-max-250x250.png"],
             [[318,
               150],
              "assets/images/resized/0005/9083/59083v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Leberstrasse 20",
    "address2": "",
    "zip_code": "1112",
    "city": "Vienna",
    "state_code": null,
    "country_code": "AUT",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "\u00e2\u201a\u00ac15 Million Brings Nabriva's 2nd Round to a Close\r\n",
    "stoned_year": 2009,
    "stoned_month": null,
    "stoned_day": null,
    "source_url": "http://www.invest-iq.com/Nabriva-closes-2nd-round-financing",
    "source_text": null,
    "source_description": "\u00e2\u201a\u00ac15 Million Brings Nabriva's 2nd Round to a Close ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Nabriva Therapeutics",
      "permalink": "nabriva-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0007/4038/74038v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0007/4038/74038v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0007/4038/74038v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  [{"external_url": "http://www.themrsa.com",
    "title": "MRSA Infections"}]}